Preventive Effects of Epigallocatechin-3-O-Gallate against Replicative Senescence Associated with p53 Acetylation in Human Dermal Fibroblasts

Figure 1

SABG expression of serially passaged RVSMCs (a) and HACs (b) in the absence or presence of 50 μM EGCG. The quantitative results showed that the RVSMCs (c) and HACs (d) at early passage (PN 3 or 5) that were not treated with EGCG did not stain blue or only a few stained, but the cells at late passage (PN 20) showed much blue staining of senescent cells. Furthermore, both cells treated with EGCG showed the number of senescent cells comparable to those with 5 PN. All variables were tested in three independent cultures for each experiment, which was repeated twice independently (𝑛=6). The results are reported as a mean ± SD and analyzed by a Tukey HSD test. ^∗𝑃<0.05 versus nontreated cells of 3 PN; ^#𝑃<0.05 versus nontreated cells of 20 PN.

(a)

(b)

(c)

(d)